已收盘 12-12 16:00:00 美东时间
-0.250
-6.94%
今日重点评级关注:HC Wainwright & Co.:维持Adicet Bio"买入"评级,目标价从4美元升至9美元;Citizens: 维持Rapport Therapeutics"跑赢大市"评级,目标价从77美元升至80美元
11-10 17:17
今日重点评级关注:HC Wainwright & Co.:维持Adicet Bio"买入"评级,目标价从4美元升至9美元;Citizens: 维持Rapport Therapeutics"跑赢大市"评级,目标价从77美元升至80美元
11-10 10:22
Canaccord Genuity analyst George Gianarikas maintains Arq (NASDAQ:ARQ) with a Buy and lowers the price target from $11 to $8.
11-08 05:37
Shares of Snap Inc (NYSE:SNAP) rose sharply in pre-market trading after the com...
11-06 19:32
Arq shares are trading lower after the company reported mixed Q3 financial resu...
11-06 06:38
Arq (NASDAQ:ARQ) reported quarterly losses of $(0.02) per share which missed the analyst consensus estimate of $0.02 by 217.65 percent. This is a 150 percent decrease over earnings of $0.04 per share from the same period
11-06 06:02
Companies Reporting Before The Bell • Avient (NYSE:AVNT) is estimated to report...
11-05 19:12
Arq Inc. released its 2024 Sustainability Report, highlighting strong financial performance with $109M revenue and EBITDA growth, alongside ESG achievements. Environmental efforts include advancing PFAS solutions, coal waste transformation, and energy efficiency. Socially, the company maintained safety records, employee growth, and community engagement. Governance improvements include enhanced ESG oversight and ethics training. Innovation include...
09-25 12:30
MIAMI, Sept. 10, 2025 /PRNewswire/ -- ARQA, the AI-native wealth management platform, has been recognized as the winner of the Disruptors Category in the 2025 WealthManagement.com Industry A...
09-10 22:00
Arq (NASDAQ:ARQ) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $(0.02) by 194.12 percent. This is a 16.67 percent increase over losses of $(0.06) per share from the same
08-12 04:34